CoChat
Sign Up
Cited by 368Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and OutcomesOrgan and Tissue Transplantation Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts

Open access
Suthanthiran, Manikkam, Schwartz, Joseph E., Ding, Ruchuang, Abecassis, Michael, Dadhania, Darshana, Samstein, Benjamin, Knechtle, Stuart J., Friedewald, John, Becker, Yolanda T., Sharma, Vijay K., Williams, Nikki M., Chang, Christina S., Hoang, Christine, Muthukumar, Thangamani, August, Phyllis, Keslar, Karen S., Fairchild, Robert L., Hricik, Donald E., Heeger, Peter S., Han, Leiya, Liu, Jun, Riggs, Michael, Ikle, David N., Bridges, Nancy D., Shaked, Abraham·2013·New England Journal of Medicine
DOI 10.1056/nejmoa1215555PMC PMC3786188
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The standard test for the diagnosis of acute rejection in kidney transplants is the renal biopsy. Noninvasive tests would be preferable. METHODS: We prospectively collected 4300 urine specimens from 485 kidney-graft recipients from day 3 through month 12 after transplantation. Messenger RNA (mRNA) levels were measured in urinary cells and correlated with allograft-rejection status with the use of logistic regression. RESULTS: A three-gene signature of 18S ribosomal (rRNA)-normalized measures of CD3ε mRNA and interferon-inducible protein 10 (IP-10) mRNA, and 18S rRNA discriminated between biopsy specimens showing acute cellular rejection and those not showing rejection (area under the curve [AUC], 0.85; 95% confidence interval [CI], 0.78 to 0.91; P<0.001 by receiver-operating-characteristic curve analysis). The cross-validation estimate of the AUC was 0.83 by bootstrap resampling, and the Hosmer-Lemeshow test indicated good fit (P=0.77). In an external-validation data set, the AUC was 0.74 (95% CI, 0.61 to 0.86; P<0.001) and did not differ significantly from the AUC in our primary data set (P=0.13). The signature distinguished acute cellular rejection from acute antibody-mediated rejection and borderline rejection (AUC, 0.78; 95% CI, 0.68 to 0.89; P<0.001). It also distinguished patients who received anti-interleukin-2 receptor antibodies from those who received T-cell-depleting antibodies (P<0.001) and was diagnostic of acute cellular rejection in both groups. Urinary tract infection did not affect the signature (P=0.69). The average trajectory of the signature in repeated urine samples remained below the diagnostic threshold for acute cellular rejection in the group of patients with no rejection, but in the group with rejection, there was a sharp rise during the weeks before the biopsy showing rejection (P<0.001). CONCLUSIONS: A molecular signature of CD3ε mRNA, IP-10 mRNA, and 18S rRNA levels in urinary cells appears to be diagnostic and prognostic of acute cellular rejection in kidney allografts. (Funded by the National Institutes of Health and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1215555

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 368

Related

See all

Metadata

Authors
Suthanthiran, M., Schwartz, J. E., Ding, R., Abecassis, M., Dadhania, D., Samstein, B., Knechtle, S. J., Friedewald, J., Becker, Y. T., Sharma, V. K., Williams, N. M., Chang, C. S., Hoang, C., Muthukumar, T., August, P., Keslar, K. S., Fairchild, R. L., Hricik, D. E., Heeger, P. S., Han, L., Liu, J., Riggs, M., Ikle, D. N., Bridges, N. D., & Shaked, A.
Affiliations
  • Weill Cornell Medicine (US)
  • Stony Brook University (US)
  • Northwestern University (US)
  • Columbia University (US)
  • Emory University (US)
  • University of Chicago (US)
  • National Institute of Allergy and Infectious Diseases (US)
  • Cleveland Clinic (US)
  • University Hospitals Cleveland Medical Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Pharmaceutical Product Development (United States) (US)
  • Rho (United States) (US)
  • University of Pennsylvania (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2013-07-04
Volume
369
Issue
1
Pages
20-31
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1215555
PMC
PMC3786188
OpenAlex
W2042953533
Cited by
363
References
18
Citations by year
2026: 15 · 2025: 26 · 2024: 22 · 2023: 20 · 2022: 25 · 2021: 34 · 2020: 19 · 2019: 28 · 2018: 20 · 2017: 31 · 2016: 45 · 2015: 36 · 2014: 31 · 2013: 11
FWCI
29.89
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Columbia Academic Commons (Columbia University)
Funders
  • Yale University
  • University of Pennsylvania
  • Emory University
  • Northwestern University
  • Cincinnati Children's Hospital Medical Center
  • Cleveland Clinic
  • National Research Foundation
  • National Institutes of Health (UL1TR000457)
  • Weill Cornell Medical College
  • School of Medicine, Emory University
  • National Institute of Allergy and Infectious Diseases (U01-AI63589, U01AI063589, R37AI051652)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
Keywords
acute cellular rejection, kidney transplantation, urinary cells, CXCL10, non-invasive diagnosis, acute antibody-mediated rejection, urinary tract infection, molecular signatures, prognostic factors, renal biopsy
MeSH terms
Acute Disease, Adult, Female, Graft Rejection, Humans, Male, Middle Aged, Prospective Studies, RNA Polymerase I, RNA, Messenger, RNA, Ribosomal, RNA, Ribosomal, 18S, ROC Curve, Sensitivity and Specificity, Kidney Transplantation, Area Under Curve, Intracellular Signaling Peptides and Proteins, Chemokine CXCL10, Transcriptome, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review